GlassScriptPhysician profile
Nicolas J Daoura
NPI 1639273956
$7,258.42
in general payments reported to CMS, 2019-2025
21 companies · $991 in 2025
The $991 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $781 · 2021: $1,007 · 2022: $740 · 2023: $2,043 · 2024: $887 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Consulting Fee: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.89 |
| Consulting Fee | $1,380.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $1,415.90 | 2023-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $990.21 | 2019-2025 | Delstrigo, Pifeltro, Zerbaxa |
| Abbvie INC. | $909.55 | 2021-2025 | Avycaz, Dalvance, Mavyret |
| Shionogi INC | $594.43 | 2021-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $531.85 | 2020-2025 | Nuzyra |
| Allergan, INC. | $443.93 | 2019-2020 | |
| Insmed, INC. | $422.99 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $274.68 | 2019-2021 | |
| Melinta Therapeutics, LLC | $272.79 | 2022-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Cumberland Pharmaceuticals, INC. | $256.18 | 2021-2025 | Vibativ |
| Emd Serono, INC. | $213.87 | 2020-2025 | Serostim |
| Cipla USA INC. | $205.52 | 2021 | |
| Gilead Sciences, INC. | $187.67 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $158.37 | 2019-2025 | Cabenuva, Dovato |
| Boston Scientific Corporation | $123.23 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $90.97 | 2023-2025 | Xerava, Zevtera, Xacduro |
| Aimmune Therapeutics, INC. | $50.81 | 2024-2025 | Vowst |
| Janssen Biotech, INC. | $44.36 | 2019 | |
| Urgo Medical North America, LLC | $25.56 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Inari Medical, INC. | $23.14 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Nabriva Therapeutics, Plc | $22.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Daoura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.